Trial abstract · §3

RETA-PH2-OBESITY — results

Primary endpoint, absolute and relative effect where derivable, and harms as reported.

Document identifier: CEI-TR-0036/3
Series: Trial abstract
Version: 2.4
Published: 09 Jan 2023
Last reviewed: 09 May 2023
Next review: 09 May 2025
Identifier: 10.71829/cei.trial.36
Certainty: Moderate
Cycle: 2023 Q1
Phase: Phase 2
Status: Reported

§3Results

§3.1Primary endpoint

Table 3. Primary endpoint as reported.

Endpoint	Result as reported	Certainty
Percentage change in body weight from baseline to week 48	Mean change −24.2 % at 12 mg versus −2.1 % with placebo	Moderate
Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed.

§3.2Endpoint hierarchy

Figure 1. Illustrative. Categorical responder proportions derived by the Institute from the reported mean change under a logistic response model. These are not the published responder proportions for this trial. The figure is published because a mean conceals the distribution of response, and the shape of that distribution is what a reader most often wants and least often gets.

§3.3Harms as reported

Table 5. Adverse events for Retatrutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.

Event	Active, %	Comparator, %	Source trial
Nausea	35.0	13.0	Phase 2 obesity trial (12 mg, 48 weeks)
Diarrhoea	29.0	9.0	Phase 2 obesity
Vomiting	24.0	2.0	Phase 2 obesity
Constipation	20.0	9.0	Phase 2 obesity
Increased heart rate	—	—	Dose-dependent rise of approximately 6–10 beats/min at higher doses, attenuating by week 24
Discontinuation for adverse events	16.0	4.0	Phase 2 obesity (highest dose cohort)

Compound Evidence Institute · CEI-TR-0036/3 · https://compoundevidence.com/trials/reta-ph2-obesity/results/ · retrieved 30 July 2026